577 related articles for article (PubMed ID: 34107450)
1. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
2. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
4. Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Quiroga D; Liebner DA; Philippon JS; Hoffman S; Tan Y; Chen JL; Lenobel S; Wakely PE; Pollock R; Tinoco G
BMC Cancer; 2020 Jun; 20(1):527. PubMed ID: 32503455
[TBL] [Abstract][Full Text] [Related]
5. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
7. Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis.
You Y; Guo X; Zhuang R; Zhang C; Wang Z; Shen F; Wang Y; Liu W; Zhang Y; Lu W; Hou Y; Wang J; Zhang X; Lu M; Zhou Y
Front Mol Biosci; 2021; 8():747650. PubMed ID: 34869583
[No Abstract] [Full Text] [Related]
8. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Brito ABC; Camandaroba MPG; de Lima VCC
Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
[TBL] [Abstract][Full Text] [Related]
9. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
12. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
15. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
16. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis.
Aboul-Fettouh N; Chen L; Ma J; Patel J; Silapunt S; Migden M
Australas J Dermatol; 2022 Feb; 63(1):36-42. PubMed ID: 34699068
[TBL] [Abstract][Full Text] [Related]
17. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
18. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.
Wang X; Wang J; Sun B; Sun Y; Liu N; Niu X; Li C; Li L; Zhang Q; Hao J; Wang X
Ann Transl Med; 2022 Sep; 10(18):961. PubMed ID: 36267758
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
Hindi N; Razak A; Rosenbaum E; Jonczak E; Hamacher R; Rutkowski P; Bhadri VA; Skryd A; Brahmi M; Alshibany A; Jagodzinska-Mucha P; Bauer S; Connolly E; Gelderblom H; Boye K; Henon C; Bae S; Bogefors K; Vincenzi B; Martinez-Trufero J; Lopez-Martin JA; Redondo A; Valverde C; Blay JY; Moura DS; Gutierrez A; Tap W; Martin-Broto J
ESMO Open; 2023 Dec; 8(6):102045. PubMed ID: 38016251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]